Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug.

Proceedings of the National Academy of Sciences of the United States of America - 29 Jul 2008

Boeckler Frank M, Joerger Andreas C, Jaggi Gaurav, Rutherford Trevor J, Veprintsev Dmitry B, Fersht Alan R

Abstract excerpt

The tumor suppressor p53 is mutationally inactivated in approximately 50% of human cancers. Approximately one-third of the mutations lower the melting temperature of the protein, leading to its rapid denaturation. Small molecules that bind to those mutants and stabilize them could be effective an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Screening Assays, Antitumor
Share to Biophysics
Share to Calorimetry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crystallography, X-Ray

Share to Genes, p53

Share to Genes, Tumor Suppressor

Share to Molecular Conformation

Share to Thermodynamics

Source

Open in PubMed Open full text

Identifiers

PMID: 18650397
DOI: 10.1073/pnas.0805326105
PMCID: PMC2492497

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18650397-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug.PMID 18650397Read ↗

Small molecule induced reactivation of mutant p53 in cancer cells.Semantic proximity Read ↗

Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs.Semantic proximity Read ↗

A Structure-Guided Molecular Chaperone Approach for Restoring the Transcriptional Activity of the p53 Cancer Mutant Y220CSemantic proximity Read ↗

An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein.Semantic proximity Read ↗

Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220CSemantic proximity Read ↗

Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators.Semantic proximity Read ↗

Structural basis for understanding oncogenic p53 mutations and designing rescue drugsSemantic proximity Read ↗

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.Semantic proximity Read ↗

Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm.Semantic proximity Read ↗

Discovery of compounds that reactivate p53 mutants in vitro and in vivo.Semantic proximity Read ↗

Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant.Semantic proximity Read ↗

Anticancer therapeutic strategies for targeting mutant p53-Y220CSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.